Haemonetics Corp（HAE）股票分析HAEHaemonetics Corp

Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Haemonetics Corp is a good buy right now due to its current price of $118.28, a forward P/E ratio of 20.33, and a gross margin of 56.98%. The recent surge of 16% in shares following the announcement of the rollout of its plasmapheresis platform indicates strong demand growth. However, the main risk is the recent net income drop to -20,147,000 USD in Q4 2026, which could affect investor sentiment if not addressed.

9 analysts cover HAE: 3 rate it Buy, 5 Hold and 1 Sell. The average price target is 88.86.